CLINICAL TRIALS PROFILE FOR EPIVIR-HBV
✉ Email this page to a colleague
505(b)(2) Clinical Trials for EPIVIR-HBV
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Combination | NCT00002234 ↗ | Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients | Completed | Bristol-Myers Squibb | Phase 2 | 1969-12-31 | The purpose of this study is to see if it is safe and effective to give HIV-infected patients a new combination of anti-HIV drugs taken once daily. |
| New Combination | NCT00002234 ↗ | Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients | Completed | Dupont Applied Biosciences | Phase 2 | 1969-12-31 | The purpose of this study is to see if it is safe and effective to give HIV-infected patients a new combination of anti-HIV drugs taken once daily. |
| New Combination | NCT00002234 ↗ | Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients | Completed | Glaxo Wellcome | Phase 2 | 1969-12-31 | The purpose of this study is to see if it is safe and effective to give HIV-infected patients a new combination of anti-HIV drugs taken once daily. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for EPIVIR-HBV
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00002168 ↗ | A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients | Completed | Bristol-Myers Squibb | N/A | 1969-12-31 | The purpose of this study is to compare the safety and effectiveness of two anti-HIV drug combinations when given to HIV-infected patients who have never been treated with anti-HIV drugs. One drug combination is stavudine (d4T) plus didanosine (ddI) plus Crixivan. The other combination is Retrovir (AZT) plus Epivir (3TC) plus Crixivan. |
| NCT00002183 ↗ | A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection | Completed | Glaxo Wellcome | Phase 1 | 1969-12-31 | To assess the safety and tolerance of multiple oral doses of 141W94 alone, in combination with 1592U89, and in combination with Retrovir and Epivir, administered to patients with HIV infection as measured by the development of clinical adverse experiences and laboratory test abnormalities. To determine the steady-state pharmacokinetics of 141W94 alone and in combination with 1592U89 after multiple oral dosing. To obtain preliminary evidence of antiretroviral activity of 141W94 alone and in combination with 1592U89, the antiretroviral effect of combined Retrovir/Epivir and the antiretroviral effect of 141W94 when added to Retrovir/Epivir or to 1592U89/Retrovir/Epivir. |
| NCT00002195 ↗ | A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients | Completed | Glaxo Wellcome | Phase 3 | 1969-12-31 | The purpose of this study is to see if it is safe and effective to add 141W94 to an anti-HIV regimen that includes retrovir plus epivir. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for EPIVIR-HBV
Condition Name
Clinical Trial Locations for EPIVIR-HBV
Trials by Country
Clinical Trial Progress for EPIVIR-HBV
Clinical Trial Phase
Clinical Trial Sponsors for EPIVIR-HBV
Sponsor Name
